✦ LIBER ✦

Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients With Breast Cancer Treated With Doxorubicin, Taxanes, and Trastuzumab

✍ Scribed by Ky, Bonnie; Putt, Mary; Sawaya, Heloisa; French, Benjamin; Januzzi, James L.; Sebag, Igal A.; Plana, Juan Carlos; Cohen, Victor; Banchs, Jose; Carver, Joseph R.; Wiegers, Susan E.; Martin, Randolph P.; Picard, Michael H.; Gerszten, Robert E.; Halpern, Elkan F.; Passeri, Jonathan; Kuter, Irene; Scherrer-Crosbie, Marielle

Book ID: 121732636
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 547 KB
Volume: 63
Category: Article
ISSN: 1558-3597
DOI: 10.1016/j.jacc.2013.10.061

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Anthracycline cardiotoxicity in breast c

Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes

✍ Luca Gianni; Emanuela Salvatorelli; Giorgio Minotti 📂 Article 📅 2007 🏛 Humana Press Inc 🌐 English ⚖ 199 KB

Cancer and Cardiovascular Disease: the U

Cancer and Cardiovascular Disease: the Use of Novel Echocardiography Measures to Predict Subsequent Cardiotoxicity in Breast Cancer Treated with Anthracyclines and Trastuzumab

✍ Gulati, Gaurav; Zhang, Kathleen W.; Scherrer-Crosbie, Marielle; Ky, Bonnie 📂 Article 📅 2014 🏛 Current Science Inc. 🌐 English ⚖ 299 KB

Quantitative HER2 protein levels predict

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab

✍ Allan Lipton; Wolfgang J. Köstler; Kim Leitzel; Suhail M. Ali; Jeff Sperinde; Jo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 492 KB 👁 2 views

## Abstract ## BACKGROUND: Only a portion of breast cancer patients currently selected for trastuzumab therapy respond. ## METHODS: Using a novel assay (HERmark) to quantify total human epidermal growth factor receptor 2 (HER2) expression, the authors examined outcomes in 102 trastuzumab‐treated

A decline in circulating HER2 DNA predic

A decline in circulating HER2 DNA predicts treatment response and survival in breast cancer patients treated with trastuzumab

✍ B. Sorensen; L.S. Mortensen; J. Andersen; E. Nexo 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 88 KB

Pilot study of gemcitabine (G) plus tras

Pilot study of gemcitabine (G) plus trastuzumab (H) in metastatic breast cancer patients with erb-2 overexpression previously treated with anthracyclines (A) and taxanes (T)

✍ L. Cirera Nogueras; Galán; M. Muñoz; B. Martinez; L. Calvo; M.A. Segui; A. Oltra 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 137 KB

5034 Troponin I and C-reactive protein a

5034 Troponin I and C-reactive protein as biomarkers for changes in left ventricular ejection fraction in patients with early stage breast cancer treated with dose-dense doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and lapatinib

✍ P.G. Morris; C. Chen; N. Lin; B. Moy; S. Come; A. Abbruzzi; E. Winer; L. Norton; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB